Methods of use of emulsion formulations of aprepitant
Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
1. An injectable emulsion, comprising:
aprepitant;
13 wt/wt % to 20 wt/wt % of an egg lecithin;
9 wt/wt % to 10 wt/wt % of soybean oil;
a co-emulsifier which is an alcohol, wherein the alcohol is present in the emulsion at less than 10 wt/wt %;
a tonicity modifier;
a pH modifier, wherein the pH modifier is sodium oleate; and
water;
wherein the ratio of egg lecithin to aprepitant is between about 20:1 to 25:1;
wherein the pH of the emulsion ranges from about 7.5 to 9.0; and,
wherein the emulsion is physically stable.
2. The emulsion of claim 1 , wherein the egg lecithin is present in the emulsion at about 16 wt/wt %.
3. The emulsion of claim 1 , wherein the egg lecithin is present in the emulsion at about 17 wt/wt %.
4. The emulsion of claim 1 , wherein the ratio of egg lecithin to aprepitant is between about 24:1 to 25:1.
5. The emulsion of claim 1 , wherein the ratio of egg lecithin to aprepitant is about 24:1.
6. The emulsion of claim 1 , wherein the ratio of egg lecithin to aprepitant is about 25:1.
7. The emulsion of claim 1 , wherein the alcohol in the emulsion is ethanol.
8. The emulsion of claim 7 , wherein the ethanol is present in the emulsion at a concentration of about 2 wt/wt % to 3 wt/wt %.
9. The emulsion of claim 1 , wherein the tonicity modifier in the emulsion is sucrose.
10. The emulsion of claim 9 , wherein the sucrose is present at a concentration of about 3 wt/wt % to 8 wt/wt %.
11. The emulsion of claim 9 , wherein the sucrose is present at a concentration of about 5 wt/wt %.
12. The emulsion of claim 1 , wherein the pH modifier in the emulsion is sodium oleate.
13. The emulsion of claim 12 , wherein the sodium oleate is present at a concentration of about 0.4 wt/wt % to 0.5 wt/wt %.
14. The emulsion of claim 1 , wherein the aprepitant is present in the emulsion at about 0.7 wt/wt %.
15. The emulsion of claim 14 , wherein the ratio of egg lecithin to aprepitant is between about 20:1 to 25:1.
16. The emulsion of claim 14 , wherein the egg lecithin is present at a concentration of about 16 wt/wt %.
17. The emulsion of claim 14 , wherein the egg lecithin is present at a concentration of about 17 wt/wt %.
18. The emulsion of claim 14 , wherein the egg lecithin is present at a concentration of about 18 wt/wt %.
19. The emulsion of claim 14 , wherein the ratio of egg lecithin to aprepitant is about 24:1.
20. The emulsion of claim 14 , wherein the ratio of egg lecithin to aprepitant is about 25:1.
21. The emulsion of claim 1 , comprising:
about 16 wt/wt % to 17 wt/wt % of the egg lecithin;
about 9 wt/wt % to 10 wt/wt % of the alcohol;
about 3 wt/wt % to 8 wt/wt % of the tonicity modifier; and
about 0.4 wt/wt % to 0.5 wt/wt % of the pH modifier.
22. The emulsion of claim 21 , wherein the ratio of egg lecithin to aprepitant is between about 24:1 to 25:1.
23. The emulsion of claim 14 , comprising:
about 16 wt/wt % to 17 wt/wt % of the egg lecithin;
about 9 wt/wt % to 10 wt/wt % of the alcohol;
about 3 wt/wt % to 8 wt/wt % of the tonicity modifier; and
about 0.4 wt/wt % to 0.5 wt/wt % of the pH modifier.
24. The emulsion of claim 23 , wherein the ratio of egg lecithin to aprepitant is between about 24:1 to 25:1.